A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Litapiprant Tablets in Healthy Subjects
Latest Information Update: 09 Mar 2021
At a glance
- Drugs Litapiprant (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Sunshine Lake Pharma
- 23 Jul 2020 Status changed from recruiting to completed.
- 20 Oct 2018 Status changed to recruiting.
- 14 Sep 2018 New trial record